BMO Capital Downgrades Regulus Therapeutics (RGLS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Regulus Therapeutics (RGLS) PT Lowered to $9 at FBR
June 28, 2016 1:35 PM EDTFBR Capital analyst Christopher James lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) to $9.00 (from $30.00) following the FDA clinical hold on RG-101 but maintained a Buy rating.
James commented, "We are lowering our price target to $9 on shares of RGLS, following Regulus' announcement yesterday that the FDA has placed its... More
Regulus Therapeutics (RGLS) PT Cut to $13.50 at Chardan Capital Following Clinical Hold
June 28, 2016 7:38 AM EDTChardan Capital Markets analyst Madhu Kumar lowered his price target on Regulus Therapeutics (NASDAQ: RGLS) 33% to $13.50 after the company announced the start of a clinical hold for RG-101 in the treatment of chronic hepatitis C virus (HCV).
Based upon the clinical hold, the firm now lowers their peak risk-adjusted RG-101 sales to $1.2 bn and NPV to $9.24... More
Regulus Therapeutics (RGLS) Shares Plummet Upon Resumption
June 27, 2016 4:45 PM EDTRegulus Therapeutics (NASDAQ: RGLS) shares resume trading, the stock is down over 50% in after-hours trading.
... MoreRegulus Therapeutics (RGLS) Announces Clinical Hold on RG-101
June 27, 2016 4:10 PM EDTRegulus Therapeutics Inc. (Nasdaq: RGLS) received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) for RG-101 for the treatment of chronic hepatitis C virus (HCV) infection has been placed on... More
